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Introduction
Type 2 diabetes mellitus (T2DM) has been associated 
with a number of complications, such as cardiovascular dis-
ease, diabetic nephropathy and infection1. Recently, with the 
markedly improved survival of T2DM patients, attributed 
to the successful treatment of cardiovascular disease and 
infection control, the relationship between T2DM and can-
cer has been attracting attention. In epidemiological studies, 
T2DM was reported to be associated with increased risks of 
colon, pancreas, mammary, liver and urinary bladder can-
cers; however, the underlying mechanisms of increased can-
cer risks in T2DM patients remain unclear2,3.
The influence of diabetes on carcinogenesis induced 
by chemical carcinogens has been investigated in the colon, 
stomach and mammary gland in experimental animals4–6. 
The number of colon tumors initiated by 1,2-dimethylhy-
drazine dihydrochloride (DMH) was increased in Otsuka 
Long-Evans Tokushima Fatty (OLETF) rats spontaneously 
developing T2DM compared with LETO rats, a non-diabetic 
strain4. Insulin resistance and hyperinsulinemia were sug-
gested as direct risk factors for colon cancer7. Furthermore, 
db/db diabetic mice were reported to be highly susceptible to 
stomach carcinogenesis induced by N-methyl-N-nitrosourea 
(MNU), possibly in association with hyperinsulinemia and 
hyperleptinemia5. On the other hand, decreased susceptibil-
ity to MNU-induced mammary carcinogenesis was report-
ed in streptozotocin-induced diabetic rats, possibly due to 
significantly lowered plasma levels of insulin and insulin-
like growth factor 1 (IGF-1) during the promotion phase of 
carcinogenesis6. Based on these findings, metabolic abnor-
malities accompanying diabetes, such as hyperinsulinemia, 
hyperleptinemia and a high plasma level of IGF-1, have been 
proposed to play a role in cancer development in DM pa-
tients.
Zucker Diabetic Fatty (ZDF) rats closely mimic human 
adult onset T2DM and its related complications due to the 
inherited homozygous leptin receptor mutation, which leads 
to obesity and insulin resistance8. T2DM does not develop 
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in lean littermate (Lean) animals8. ZDF animals show insu-
lin resistance from the time of weaning but maintain normo-
glycemia until 8–10 weeks of age because of the compen-
satory hypersecretion of insulin9. ZDF rats develop overt 
diabetes and have defects in insulin secretion from around 
8–10 weeks of age10.
The purpose of the present study was to investigate 
the modifying effects of T2DM on carcinogenesis in dia-
betic ZDF rat using a multiorgan carcinogenesis bioassay. 
The multiorgan carcinogenesis bioassay uses treatment with 
five types of genotoxic carcinogens, namely N-diethylnitro-
samine (DEN), MNU, N-butyl-N-(4-hydroxybutyl) nitrosa-
mine (BBN), diisopropanolnitrosamine (DHPN) and DMH, 
with target organs including the liver, kidneys, urinary blad-
der, stomach, small intestine, colon, lungs and thyroid11,12. 
At  the  end  of  the  experiment,  histopathological  analysis 
was performed to investigate cancer development. We also 
investigated the serum levels of several biologically active 
compounds, including insulin, leptin, adiponectin and IGF-
1. Furthermore, to elucidate possible mechanisms underly-
ing the modifying effects of T2DM, we analyzed alterations 
of the gene expression in the bladder urothelium in a 4-week 
BBN bladder carcinogenicity study.
Materials and methods
Animals
Five-week-old ZDF and control Lean rats were pur-
chased from Charles River Laboratories Japan, Inc. (Kana-
gawa, Japan) and used after a 1-week acclimation period. 
They were housed in plastic cages (one rat/cage for ZDF 
rats, two rats/cage for Lean rats) in an environmentally-con-
trolled room maintained at a temperature of 22 ± 2°C and 
relative humidity of 44 ± 5%, with a 12-h light/dark cycle 
and free access to water and food (MF pellet diet; Oriental 
Yeast Co., Ltd., Tokyo, Japan). Body weight and food in-
take were measured weekly during the experimental period. 
Water intake was measured three times a week in the first 4 
weeks and once a week thereafter.
Chemicals
DEN,  DMH  and  BBN  were  purchased  from  Tokyo 
Chemical Industry Co., Ltd. (Tokyo, Japan). MNU was pur-
chased from Wako Pure Chemical Industries, Ltd. (Osaka, 
Japan), and DHPN was purchased from Nacalai Tesque Inc. 
(Kyoto, Japan).
Experimental protocol
Experimental protocols were approved by the Institu-
tion Animal Care and Use Committee of Osaka City Uni-
versity Medical School. The experimental protocol of the 
rat multiorgan carcinogenesis bioassay used in experiment 1 
is shown in Fig. 111,12. Twenty-six male ZDF rats at 6 weeks 
of  age  were  divided  randomly  into  two  groups.  Twenty 
ZDF rats were treated with five carcinogens, DEN, MNU, 
BBN,  DMH  and  DHPN  (DMBDD),  as  follows:  a  single 
i.p. injection of DEN (100 mg/kg b.w.) at the beginning of 
the experiment, followed by four i.p. injections of MNU 
(20 mg/kg b.w.) from week 1 to 2, and four s.c. injections of 
DMH (40 mg/kg b.w.) from week 3 to 4. Also, 0.05% BBN 
in drinking water was administered to rats for two weeks 
from commencement of the experiment, and then DHPN in 
drinking water was administered to the rats for the follow-
ing 2 weeks. Six control ZDF rats were administered tap 
water and received vehicle injections (0.9% saline) in the 
same manner. Twenty-seven male Lean rats at 6 weeks of 
age were divided randomly into two groups and treated with 
DMBDD (20 rats) and vehicle (7 rats), respectively, as de-
scribed above. DHPN was administered to Lean rats at a 
concentration of 0.1% in drinking water. As ZDF rats were 
drinking more water than Lean rats from week 3 to 4, the 
concentrations of DHPN administered to the ZDF rats were 
diluted to give the same amount of DHPN per b.w. as the 
Lean rats based on their body weight and water intake. Af-
ter the initiation treatments, all rats were maintained with-
out any treatment until the end of the study. Blood glucose 
was examined weekly from week 3 to 7 and once every two 
weeks from week 8 to 30 via the tail vein using a blood 
glucose test meter (Glutest Ace R; Sanwa Kagaku Kenky-
usho Co., Ltd., Nagoya, Japan). At the end of week 30, all 
surviving animals were euthanized under deep anesthesia, 
target organs were taken out and the liver, kidney and spleen 
weights were measured. All target organs were fixed in 10% 
phosphate-buffered formalin and embedded in paraffin for 
histopathological examination. Blood serum was collected 
for biochemical analyses. Part of the liver tissues was snap 
frozen in liquid nitrogen and stored at -80°C.
In experiment 2, 12, 6-week-old male ZDF or Lean 
rats were divided randomly into two groups each. BBN in 
drinking water was administered for 4 weeks from com-
mencement of the experiment to ZDF (6) or Lean (6) rats. 
The remaining 6 ZDF and 6 Lean rats were administered 
tap water. Given the differences in water intake and body 
weight between the ZDF and Leans rats, water intake and 
body weights were measured three times a week, and the 
BBN concentration was adjusted to give the same amount of 
BBN per b.w. to both strains of rats based on the water intake 
per body weight per day from commencement of the experi-
ment. Briefly, 0.05% BBN was administered to the strain of 
rats drinking less water (g/kg, b.w.), and the concentration 
of BBN was diluted and administered to the strain of rats 
drinking more water. Blood glucose was examined weekly 
from week 1 to 4. At week 4, all rats were euthanized un-
der deep anesthesia, and blood serum was collected for bio-
chemical analyses. The bladder mucosa was harvested using 
the method described previously13. Part of the liver tissues 
was snap frozen in liquid nitrogen and stored at -80°C.
Blood biochemistry analysis
Blood  biochemistry  was  analyzed  at  the  end  of  the 
experiments (week 30 in experiment 1 and week 4 in ex-
periment 2) by Mitsubishi Chemical Medience Corporation 
(Tokyo, Japan). The serum levels of insulin, leptin, adipo-
nectin, IGF-1, tumor necrosis factor a (TNFa) and inter-
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leukin-6 (IL-6) of all surviving rats were measured using 
rat ELISA kits (insulin, Shibayagi Co., Ltd., Gunma, Japan; 
leptin, Morinaga Institute of Biological Science, Inc., Kana-
gawa, Japan; adiponectin, Otsuka Pharmaceutical Co., Ltd., 
Tokyo, Japan; IGF-1, TNFa and IL-6, R&D Systems, Inc., 
Minneapolis, MN, USA) according to the manufacturers’ 
instructions.
RNA preparation and real-time quantitative PCR
RNA from the bladder mucosa and liver was isolated 
using TRIZOL Reagent (Life Technologies Japan Ltd., To-
kyo, Japan) according to the manufacturer’s instructions. 
Synthesis of cDNA was performed with 600 ng RNA using 
an Advantage RT-for-PCR kit (Takara Bio, Inc., Shiga, Ja-
pan). Real-time quantitative PCRs for phosphatidylinositol 
3-kinase (PI3K), p53, PCNA and b-actin as an internal con-
trol for the bladder mucosa and IGF-1 and rsp18 as an inter-
nal control for the liver were performed using an Applied 
Biosystems  7500  Fast  Real-Time  PCR  System  (Applied 
Biosystems, Inc., Tokyo, Japan) as described previously13,14. 
Briefly,  20 µl  containing  1 µl  of  the  respective  TaqMan 
Gene Expression Assays (Applied Biosystems, Inc., Tokyo, 
Japan), 10 µl TaqMan Fast Universal PCR Master Mix (Ap-
plied Biosystems, Inc., Tokyo, Japan) and 5 µl diluted cDNA 
were applied to a Fast 96-well Reaction Plate.
Serially diluted standard cDNA was included in each 
TaqMan  PCR  reaction  to  create  standard  curves.  The 
amounts of gene products in the test samples were estimated 
relative to the respective standard curves. Values for target 
genes were normalized to those for b-actin or rsp18.
Statistical analysis
All mean values are reported as means ± SD. Statisti-
cal analyses were performed using the StatLight program 
(Yukms Co., Ltd., Tokyo, Japan). Homogeneity of variance 
analysis was performed by the F test. Differences in mean 
values between the control and carcinogen-treated groups 
were evaluated by Student’s t-test when the variance was 
homogeneous and Welch’s t-test when the variance was het-
erogeneous. Incidence was assessed by Fisher’s exact prob-




Experiment  1:  Five  DMBDD-treated  ZDF  rats  were 
found dead or moribund at weeks 17, 21, 22, 27 and 29. Fur-
thermore, two control ZDF rats were found dead or mori-
bund without any discernible cause at weeks 21 and 26. All 
DMBDD-treated and control Lean rats were alive at the end 
of the study. As bladder, small intestine and liver tumors 
27
Fig. 1.  Experimental protocol of experiment 1 (DMBDD model).28 Modifying Effects of Type 2 Diabetes on Carcinogenesis
were found in the DMBDD-treated ZDF rat that died at 
week 17, all rats were included in the effective animals for 
histopathological analysis.
Body weight curves, final body weight and absolute 
and relative organ weights of the rats in experiment 1 are 
shown in Fig. 2A and Table 1. The body weights of both the 
DMBDD-treated ZDF and Lean rats were significantly de-
creased during administration of DMBDD compared with 
the control rats of the same genotype; however, the final 
body weights of both the ZDF and Lean rats administered 
DMBDD were not significantly changed as compared with 
the control rats of the same genotype. The body weights of 
the ZDF rats were significantly higher during the DMBDD 
treatment period but were significantly lower than those of 
the Lean rats at the end of the study irrespective of whether 
or not they received carcinogen treatment.
During BBN treatment (weeks 1 and 2), the total BBN 
intake of the ZDF rats (0.54 ± 0.07 mg/kg b.w.) was signifi-
cantly lower than that of the Lean rats (0.63 ± 0.04 mg/kg 
b.w.). During DHPN treatment (weeks 3 and 4), almost the 
same total amount of DHPN was given to both strain rats 
(1.3 ± 0.4 mg/kg b.w. for the ZDF rats and 1.3 ± 0.1 mg/
kg b.w. for the Lean rats) by adjusting the concentration of 
DHPN based on the water intake and body weight, as de-
scribed in the Methods.
DMBDD administration inhibited food intake of both 
the ZDF and Lean rats compared with the control rats of 
the same genotype. Food intake was significantly increased 
in  the  DMBDD-treated  and  non-treated  ZDF  rats  when 
compared with the Lean rats receiving the same treatment 
throughout the experiment (data not shown).
The  absolute  liver  and  spleen  weights  and  relative 
spleen weight of the DMBDD-treated ZDF rats were sig-
nificantly higher than those of the control ZDF rats. Fur-
thermore, the absolute and relative spleen weights in the 
DMBDD-treated  Lean  group  were  significantly  elevated 
compared with those of the Lean control animals.
Experiment 2: All rats survived to the end of the study. 
Fig. 2.  Time course of body weight and blood glucose level in experiment 1 (A, B) and experiment 2 (C, D).
a P<0.05 vs. control rats of the same genotype.29 Ishii, Wei, Kakehashi et al.
Body weight curves are shown in Fig. 2C. The average body 
weights of the ZDF rats were significantly higher than those 
of the Lean rats throughout the experiment. BBN treatment 
had no effect on the body weights of the ZDF and Lean rats. 
There was no significant difference in the total intake of 
BBN between ZDF (1.4 ± 0.5 mg/kg b.w.) and Lean rats (1.1 
± 0.0 mg/kg b.w.).
Time course changes of blood glucose level
Time course changes of the blood glucose level in ex-
periments 1 and 2 are shown in Fig. 2B and D, respectively.
In  experiment  1,  the  blood  glucose  levels  were  sig-
nificantly higher in the DMBDD-treated and control ZDF 
rats throughout the experimental period compared with the 
Lean rats receiving the same treatment, respectively. The 
level of blood glucose was significantly suppressed only in 
the DMBDD-treated ZDF rats compared with the control 
ZDF rats at weeks 3–5, possibly due to the significant de-
crease of food intake during weeks 1–5 caused by DMBDD 
treatment.
In experiment 2, the blood glucose levels of the BBN-
initiated and control ZDF rats were significantly elevated 
compared with the Lean rats receiving the same treatment 
from week 2 to 4; however, BBN treatment had no effect on 
the blood glucose level in the ZDF and Lean rats.
Blood biochemistry
The results of the blood biochemistry analysis in ex-
periments 1 and 2 are shown in Table 2.
In experiment 1, the level of hemoglobin A1c (HbA1c), 
Table 1.  Final Body and Organ Weights (Experiment 1)
  DMBDD Control
ZDF Lean ZDF Lean
Initial no. of rats 20 20 6 7
Final no. of rats 15 20 4 7
Survival rate (%) 75 100 67 100
Final body weight (g) 367 ± 19 416 ± 24 355 ± 41 411 ± 32
Absolute (g)
   Liver 18.0 ± 2.4a 10.6 ± 0.9 15.0 ± 3.8 10.9 ± 0.9
   Kidneys 4.4 ± 2.7 2.3 ± 0.1 3.6 ± 0.3 2.2 ± 0.2
   Spleen 0.9 ± 0.5a 0.6 ± 0.1a 0.4 ± 0.2 0.5 ± 0.0
Relative (g/100g bw)
   Liver 4.9 ± 0.6 2.5 ± 0.1a 4.4 ± 0.9 2.7 ± 0.1
   Kidneys 1.2 ± 0.7 0.5 ± 0.0 1.1 ± 0.1 0.5 ± 0.0
   Spleen 0.2 ± 0.2a 0.2 ± 0.0a 0.1 ± 0.0 0.1 ± 0.0
a P<0.05 vs. control rats of the same genotype.
Table 2.  Blood Biochemistry
Experiment 1 DMBDD Control
week 30 ZDF Lean ZDF Lean
HbA1c (%) 8.3 ± 0.7*, a 3.3 ± 0.1 9.6 ± 0.5* 3.3 ± 0.1
Glucose (mg/dl) 479 ± 45* 137 ± 22 512 ± 51* 129 ± 8
T-Cho (mg/dl) 241 ± 69*, a 92 ± 19 404 ± 98* 92 ± 10
TG (mg/dl) 740 ± 353* 51 ± 14 1053 ± 404* 61 ± 10
AST (IU/l) 390 ± 222* 159 ± 38 618 ± 208* 148 ± 35
ALT (IU/l) 428 ± 265*, a 61 ± 51a 783 ± 353* 32 ± 3
g-GTP (IU/l) 27 ± 15*, a 2 ± 1a 72 ± 28* 1 ± 0
Experiment 2 BBN Control
week 4 ZDF Lean ZDF Lean
HbA1c (%) 5.8 ± 0.6* 3.2 ± 0.0 5.6 ± 0.6* 3.2 ± 0.0
Glucose (mg/dl) 311 ± 62* 93 ± 21 261 ± 86* 102 ± 6
T-Cho (mg/dl) 99 ± 12* 66 ± 5 97 ± 9* 71 ± 4
TG (mg/dl) 304 ± 127* 26 ± 7 377 ± 119* 24 ± 6
AST (IU/l) 454 ± 331 170 ± 16 351 ± 177* 152 ± 20
ALT (IU/l) 333 ± 319 38 ± 3 234 ± 171* 39 ± 4
g-GTP (IU/l) 6 ± 5 2 ± 1 4 ± 1* 2 ± 0
* P<0.05 vs. Lean rats receiving the same treatment. a P<0.05 vs. control rats of the same genotype. HbA1c, 
hemoglobin A1c; T-Cho, total cholesterol; TG, triglyceride; AST, aspartate aminotransferase; ALT, alanine amino-
transferase; g-GTP, g-glutamyl transpeptidase.30 Modifying Effects of Type 2 Diabetes on Carcinogenesis
one of the characteristics of diabetes, was significantly high-
er in both the DMBDD-treated and control ZDF animals 
than in the Lean rats receiving the same treatment. Further-
more, the total cholesterol (T-Cho) and triglyceride (TG) 
levels  were  also  significantly  increased  in  the  DMBDD-
administered and control ZDF rats but not in the Lean rats 
receiving the same treatment.
In experiment 2, the levels of HbA1c, T-Cho and TG 
were significantly higher in both the BBN-treated and con-
trol ZDF rats than in the Lean rats receiving the same treat-
ment. Moreover, no influence of BBN treatment was appar-
ent on HbA1c, T-Cho and TG in both the ZDF and Lean rats.
Histopathological findings in experiment 1
Table 3 summarizes the data on the incidence and mul-
tiplicity of preneoplastic and neoplastic lesions induced by 
DMBDD administration. No tumors were found in the con-
trol ZDF and Lean rats. Macroscopically, several very large 
tumors occupying the whole urinary bladder were found in 
the DMBDD-treated ZDF rats but not in the Lean rats (Fig. 
3). Histological examination demonstrated significant eleva-
tion of the incidences and multiplicities of transitional cell 
carcinomas (TCC: 55%, 0.7 ± 0.8/rat) and total tumors (pap-
illoma +TCC: 70%, 1.0 ± 0.9/rat) in the DMBDD-adminis-
tered ZDF animals as compared with the DMBDD-initiated 
Lean rats (TCC, 5% and 0.1 ± 0.2/rat; total tumors, 25% and 
0.3 ± 0.6/rat).
The incidences and multiplicities of colon adenocarci-
noma and total colon tumors (adenocarcinoma, 50% and 0.8 
± 0.9/rat; total tumors, 60% and 1.0 ± 1.0/rat) were signifi-
cantly increased in the DMBDD-treated ZDF rats as com-
pared with the DMBDD-treated Lean rats (adenocarcinoma, 
15% and 0.2 ± 0.5/rat; total tumors, 20% and 0.3 ± 0.6/rat). 
Furthermore, the incidences and multiplicities of small in-
testine adenocarcinoma and total tumors were significantly 
higher in the DMBDD-administered ZDF rats (adenocarci-
noma, 45% and 0.7 ± 1.0/rat; total tumors, 50% and 0.8 ± 
1.0/rat) than in the DMBDD-treated Lean animals (no tumor 
was found).
The incidence and multiplicity of hepatocellular ad-
enoma were significantly increased in the DMBDD-treated 
ZDF rats (40%, 0.6 ± 0.8/rat) compared with the DMBDD-
Table 3.  Histopathological Findings (Experiment 1)
Site and type of lesion Incidence (%) Multiplicity (No./rat)
DMBDD Control DMBDD Control
ZDF Lean ZDF Lean ZDF Lean ZDF Lean
Effective no. of rats b 20 20 6 7 20 20 6 7
Urinary bladder Simple hyperplasia 19 (95)a 14 (70)a 0 (0) 0 (0) - - - -
PN hyperplasia 9 (45) 6 (30) 0 (0) 0 (0) 1.0 ± 1.3a 0.4 ± 0.7a 0 0
Papilloma 4 (20) 4 (20) 0 (0) 0 (0) 0.3 ± 0.7 0.3 ± 0.6 0 0
TCC 11 (55)*, a 1 (5) 0 (0) 0 (0) 0.7 ± 0.8*, a 0.1 ± 0.2 0 0
Total tumors c 14 (70)*, a 5 (25) 0 (0) 0 (0) 1.0 ± 0.9*, a 0.3 ± 0.6a 0 0
Colon Adenoma 1 (5) 0 (0) 0 (0) 0 (0) 0.1 ± 0.2 0 0 0
Adenocarcinoma 10 (50)* 3 (15) 0 (0) 0 (0) 0.8 ± 0.9*, a 0.2 ± 0.5 0 0
Mucinous carcinoma 3 (15) 1 (5) 0 (0) 0 (0) 0.2 ± 0.4 0.1 ± 0.2 0 0
Total tumors 12 (60)*, a 4 (20) 0 (0) 0 (0) 1.0 ± 1.0*, a 0.3 ± 0.6 0 0
Small intestine Adenocarcinoma 9 (45)* 0 (0) 0 (0) 0 (0) 0.7 ± 1.0* 0 0 0
Mucinous carcinoma 1 (5) 0 (0) 0 (0) 0 (0) 0.1 ± 0.2 0 0 0
Total tumors 10 (50)* 0 (0) 0 (0) 0 (0) 0.8 ± 1.0*, a 0 0 0
Liver Adenoma 8 (40)* 1 (5) 0 (0) 0 (0) 0.6 ± 0.8*, a 0.1 ± 0.2 0 0
Kidney Adenoma 4 (20) 7 (35) 0 (0) 0 (0) 0.2 ± 0.4a 0.5 ± 0.7a 0 0
Mesenchymal tumor 5 (25) 2 (10) 0 (0) 0 (0) 0.3 ± 0.4a 0.1 ± 0.3 0 0
Nephroblastoma 9 (45) 3 (15) 0 (0) 0 (0) 0.7 ± 0.9*, a 0.2 ± 0.4 0 0
TCC 2 (10) 0 (0) 0 (0) 0 (0) 0.2 ± 0.5 0 0 0
Total tumors 12 (60)a 9 (45) 0 (0) 0 (0) 1.3 ± 1.2a 0.7 ± 0.9a 0 0
Lung Adenoma 5 (25)* 20 (100)a 0 (0) 0 (0) 0.4 ± 0.7*, a 3.7 ± 2.0a 0 0
Carcinoma 3 (15) 3 (15) 0 (0) 0 (0) 0.2 ± 0.5 0.3 ± 0.8 0 0
Total tumors 7 (35)* 20 (100)a 0 (0) 0 (0) 0.6 ± 0.8*, a 4.0 ± 2.4a 0 0
Thyroid gland Follicular adenoma 1 (5) 2 (10) 0 (0) 0 (0) 0.1 ± 0.4 0.1 ± 0.3 0 0
Follicular carcinoma 0 (0)* 5 (25) 0 (0) 0 (0) 0* 0.3 ± 0.4a 0 0
Total tumors 1 (5)* 7 (35) 0 (0) 0 (0) 0.1 ± 0.4 0.4 ± 0.5a 0 0
Esophagus Papilloma 3 (15) 0 (0) 0 (0) 0 (0) 0.2 ± 0.4 0 0 0
Forestomach SCC 1 (5) 0 (0) 0 (0) 0 (0) 0.1 ± 0.2 0 0 0
* P<0.05 vs. Lean rats receiving the same treatment.  a P<0.05 vs. control rats of the same genotype. PN, papillary or nodular; TCC, transitional 
cell carcinoma; SCC, squamous cell carcinoma.  b Number of rats found dead or moribund from week 17 to 30. c Papilloma + TCC.31 Ishii, Wei, Kakehashi et al.
treated Lean group (5%, 0.1 ± 0.2/rat). No hepatocellular 
carcinomas were found in the DMBDD-initiated ZDF and 
Lean rats.
No renal cell carcinoma was observed in any groups. 
There were no significant differences in renal cell adenoma 
between the DMBDD-treated ZDF and Lean rats. The mul-
tiplicity of nephroblastoma in the DMBDD-treated ZDF rats 
(0.7 ± 0.9/rat) was significantly increased compared with the 
DMBDD-administered Lean animals (0.2 ± 0.4/rat).
On the other hand, the incidences and multiplicities of 
adenoma and total tumors in lung and thyroid follicular car-
cinoma were significantly decreased in the DMBDD-treated 
ZDF rats compared with the DMBDD-initiated Lean group.
Serum levels of insulin, leptin, adiponectin and IGF-1
In  experiment  1,  the  serum  insulin  level  in  the 
DMBDD-treated ZDF rats was significantly higher than in 
the treated Lean groups (Fig. 4A, P<0.001). Furthermore, a 
significant increase in serum leptin level was found in the 
ZDF rats compared with the Lean rats receiving the same 
treatment  (Fig  4C;  DMBDD-treated,  P<0.0001;  control, 
P<0.05). Moreover, there was a significant decrease in the 
serum adiponectin level in the ZDF rats compared with the 
Lean rats receiving the same treatment (Fig. 4E; DMBDD-
treated, P<0.0001; control, P<0.05). In contrast to our ex-
pectation, the serum levels of IGF-1 of the DMBDD-treated 
and control ZDF rats were significantly decreased compared 
with the Lean rats receiving the same treatment (Fig. 4G; 
DMBDD-treated, P<0.0001; control, P<0.0001).
In experiment 2, the serum insulin level was signifi-
cantly increased in the BBN-treated and control ZDF rats 
compared with the Lean rats receiving the same treatment 
(Fig. 4B; BBN-treated, P<0.0001; control, P<0.0001). Sim-
ilarly, the serum leptin level in the ZDF rats was signifi-
cantly increased compared with the Lean rats receiving the 
same treatment (Fig. 4D; BBN-treated, P<0.0001; control, 
P<0.0001); however, no significant differences were appar-
ent in the serum level of adiponectin and IGF-1 (Fig. 4F and 
H).
The TNFa and IL-6 serum levels were under the limit 
of detection.
IGF-1 mRNA expression in the liver
Since there was no increase of the IGF-1 level in the 
serum of ZDF rats at weeks 4 and 30, its mRNA expression 
level was examined in the liver, which is the main organ in 
which IGF-1 is produced. IGF-1 mRNA expression was in-
hibited in the liver of the DMBDD-treated and control ZDF 
rats compared with the Lean rats receiving the same treat-
ment at week 30 in experiment 1 but without significance 
(Fig. 5A). Furthermore, there was a significant decrease of 
IGF-1 mRNA expression in the BBN-treated and control 
ZDF rats compared with the Lean rats receiving the same 
treatment at week 4 in experiment 2 (Fig. 5B; BBN-treated, 
P<0.05; control, P<0.001).
PI3K, p53 and PCNA mRNA expression in the bladder 
epithelium of BBN-treated rats (experiment 2)
Since alterations of the serum levels of insulin, leptin 
and adiponectin were observed, we further investigated the 
downstream effector molecules of these receptors. 
Significant increases of PI3K mRNA expression in the 
bladder epithelium of the BBN-initiated and control ZDF 
rats were found compared with the Lean rats receiving the 
same treatment (Fig. 6A; BBN-treated, P<0.0001; control, 
P<0.001).
Four-week  treatment  with  BBN  significantly  de-
creased the p53 mRNA expression level in the urothelium 
of the ZDF rats but had no effect on the Lean rats (Fig. 6B, 
P<0.001). Furthermore, p53 mRNA expression was signifi-
cantly inhibited in the BBN-treated ZDF rats compared with 
the treated Lean animals (Fig. 6B, P<0.05).
The expression of mRNA of PCNA, which is a mark-
er for cell proliferation, was significantly increased in the 
BBN-treated ZDF rats compared with the control ZDF ani-
mals (Fig. 6C, P<0.05) and showed a tendency to increase 
as compared with the BBN-treated Lean rats.
Discussion
The present study demonstrated enhancement effects 
of T2DM on urinary bladder, colon and liver carcinogenesis 
in ZDF type 2 diabetes rats, indicating the high multiorgan 
carcinogenic susceptibility of this strain of rats. In epidemi-
ological studies, T2DM was reported to be associated with 
Fig. 3.  Macroscopic view of the urinary bladder in experiment 1. A: 
DMBDD-treated ZDF rats. B: DMBDD-treated Lean rats.32 Modifying Effects of Type 2 Diabetes on Carcinogenesis
Fig. 4.  Serum levels of insulin, leptin, adiponectin and IGF-1 in ZDF and Lean rats. Data from ex-
periment 1 (A, C, E and G) and experiment 2 (B, D, F and H). Serum concentrations of insulin 
(A and B), leptin (C and D), adiponectin (E and F) and IGF-1 (G and H) were measured by 
ELISA. *, ** and ***: P<0.05, P<0.001 and P<0.0001, respectively, vs. Lean rats receiving 
the same treatment.33 Ishii, Wei, Kakehashi et al.
elevation of colon, pancreas, mammary, liver and urinary 
bladder cancers2,3. To the best of our knowledge, this study 
provides the first experimental evidence for a relationship 
between DM and urinary bladder cancer.
Several serum changes in T2DM patients have been 
suggested to be responsible for the increased cancer risks, 
including  increases  in  insulin,  IGF-1,  leptin,  TNFa  and 
IL-6,  as  well  as  decreased  adiponectin15.  In  the  present 
study, the serum insulin level was significantly higher in 
the DMBDD-treated ZDF rats than in the DMBDD-treated 
Lean rats at week 30. It has been reported that hyperinsu-
linemia by injection of insulin enhanced the tumorigenesis 
of azoxymethane-induced colon carcinogenesis in rats16,17. 
Furthermore,  hyperinsulinemia  is  considered  to  promote 
carcinogenesis not only directly but also indirectly by in-
creasing the synthesis of IGF-118. Unexpectedly, the serum 
level of IGF-1 was significantly lower in the ZDF rats than 
in the Lean rats irrespective of whether or not they received 
carcinogen treatment at week 30, and there was no signifi-
cant difference at week 4 between the two strains of rats. In 
contrast, the IGF-1 mRNA expression level in the liver, the 
major site of IGF-1 synthesis, was significantly lower in the 
ZDF rats than in the Lean rats receiving the same treatment 
at week 4 but was not significant at week 30 between the two 
strains of rats. Further study examining the protein expres-
sion level of IGF-1 in the liver to explain this discrepancy is 
necessary. Nevertheless, the changes of serum IGF-1 were 
not related to the increased cancers of the urinary bladder, 
colon and liver under the present conditions.
In recent studies, leptin, a hormone secreted by adi-
pocytes, was indicated to act as a mitogen and angiogenic 
factor in addition to its neuroendocrine function19. Further-
more, epidemiological studies have shown that an elevated 
level of serum leptin was associated with a high risk of 
colorectal cancer in men20 and breast cancer21. Meanwhile, 
adiponectin, which is also an adipocyte-secreted hormone, 
was reported to have an antiproliferative effect22; thus, low 
adiponectin concentrations were associated with malignan-
cies in the colon23 or mammary gland24. In the present study, 
neither DMBDD initiation nor BBN treatment affected the 
serum levels of leptin or adiponectin in the ZDF and Lean 
rats; however, the serum level of leptin was significantly 
higher and the serum adiponectin level was significantly 
lower in the ZDF rats than in the Lean rats receiving the 
same treatment at week 30. Therefore, the elevation of leptin 
and decrease of adiponectin may represent a highly suscep-
tible risk of carcinogenesis of the urinary bladder, colon and 
liver.
Recently, epidemiological studies have clearly indicat-
ed that individuals with diabetes have an increased risk of 
bladder cancer3; however, the mechanisms by which diabe-
tes mellitus contributes to bladder carcinoma are not clear. 
In this study, both the incidence and multiplicity of bladder 
cancer were significantly increased in the DMBDD-treated 
ZDF rats compared with the treated Lean rats in the 30-week 
multiorgan carcinogenicity study. In the 4-week BBN blad-
der carcinogenicity study, the serum insulin level at week 4 
was significantly increased in the treated and control ZDF 
rats compared with the Lean rats receiving the same treat-
ment. Similarly, the serum leptin level in the ZDF rats was 
significantly increased compared with the Lean rats receiv-
ing the same treatment at week 4. On the other hand, no sig-
nificant differences were apparent in the serum adiponectin 
level at week 4. Thus, changes of insulin and leptin, but not 
adiponectin levels, may be related to the high susceptibility 
of ZDF rats to bladder carcinogenesis from an early stage 
of carcinogenesis. Insulin and leptin have been reported to 
activate the PI3K signaling pathway15, which is known to be 
associated with malignant behavior, including cell growth, 
proliferation and cell survival25. Furthermore, its activation 
of PI3K has been demonstrated to be responsible for carci-
nogenesis in regard to bladder, colon, liver and other can-
cers26–29. High mRNA expression levels of PI3K in the ZDF 
rats suggested that the PI3K pathway may be responsible 
for the high susceptibility to bladder carcinogenesis of rats 
with T2DM.
Fig. 5.  IGF-1 mRNA expression in the liver. * and **: P<0.05 and P<0.001, respectively, vs. Lean rats 
receiving the same treatment.34 Modifying Effects of Type 2 Diabetes on Carcinogenesis
In addition, the decrease of p53 in obesity has been 
demonstrated to play an important role in obesity-associat-
ed cancers, such as breast and prostate cancer30,31. The low 
mRNA expression level of p53 in the BBN-treated ZDF rats 
compared with the BBN-treated Lean rats may be respon-
sible, at least in part, for their high susceptibility to bladder 
carcinogenesis.
No increased risk of lung cancer in diabetes was found 
in a recent epidemiological study32. With regard to the rela-
tionship between diabetes and thyroid cancer risk, there is 
no report available in the published literature. The findings 
of the present study that the incidences and multiplicities 
of lung tumors and thyroid follicular carcinoma were sig-
nificantly decreased in the DMBDD-treated ZDF rats com-
pared with the DMBDD-initiated Lean group indicate a low 
susceptibility of ZDF rats to lung and thyroid carcinogene-
sis in this model. However, the mechanism by which T2DM 
affects lung and thyroid carcinogenesis and whether these 
findings are relevant to human lung and thyroid cancers are 
not currently clear.
In conclusion, our results demonstrated that urinary 
bladder, colon and liver carcinogenesis are enhanced in ZDF 
type 2 diabetes rats. The possible mechanisms are related 
to increased serum levels of insulin and leptin and a de-
creased serum level of adiponectin. Furthermore, the high 
susceptibility to bladder carcinogenesis in T2DM might be a 
consequence of PI3K pathway activation and decreased p53 
expression. Further studies to analyze the mechanisms un-
derlying the high susceptibility of T2DM rats to colon and 
liver carcinogenesis are necessary.
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